scispace - formally typeset
Journal ArticleDOI

Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: An expert consensus

TLDR
Substantial evidence exists that patients receiving LMWH for an ACS can safely undergo cardiac catheterization and percutaneous coronary intervention, and concerns regarding the transition of these patients from the medical service to the cardiacCatheterization laboratory should not impede the upstream use of LMWH.
About
This article is published in American Heart Journal.The article was published on 2002-10-01. It has received 59 citations till now. The article focuses on the topics: Heart catheterization & Percutaneous coronary intervention.

read more

Citations
More filters
Journal Article

Aspirin, heparin, or both to treat acute unstable angina

TL;DR: In this article, the usefulness of aspirin (325 mg twice daily), heparin (1000 units per hour by intravenous infusion), and a combination of the two in the early management of acute unstable angina pectoris in a double-blind, randomized, placebo-controlled trial involving 479 patients was tested.
Journal Article

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article : A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines

TL;DR: WRITING COMMITTEE MEMBERS Sidney C. Smith, Jr, MD, F ACC, FAHA, Chair; Ted E. O’Neill,MD, FACC, FSCAI; Hartzell V. Schaff, MD; Patrick L. Whitlow,MD; David O. Williams, MD.
Journal ArticleDOI

JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome.

TL;DR: This document is an English version of JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome reported at the Japanese Circulation Society Joint Working Groups performed in 2018.
References
More filters
Journal ArticleDOI

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

TL;DR: Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.
Journal ArticleDOI

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

TL;DR: Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, markedly reduces the risk of acute ischemic complications in patients undergoing percutaneous coronary revascularization, without increasing the riskof hemorrhage.
Journal ArticleDOI

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

TL;DR: Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase.
Journal ArticleDOI

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

TL;DR: Platelet glycoprotein-IIb/IIIa blockade with abciximab substantially improves the safety of coronary-stenting procedures and is safer than stenting without abcximab.
Related Papers (5)